Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall.
The anatomical and functional arrangement of the gastrointestinal tract suggests that this organ, beside its digestive and absorptive functions, regulates the trafficking of macromolecules between the environment and the host through a barrier mechanism. Under physiological circumstances, this trafficking is safeguarded by the competency of intercellular tight junctions, structures whose physiological modulation is mediated by, among others, the recently described protein zonulin. To prevent harm and minimize inflammation, the same paracellular pathway, in concert with the gut-associated lymphoid tissue and the neuroendocrine network, controls the equilibrium between tolerance and immunity to nonself antigens. The zonulin pathway has been exploited to deliver drugs, macromolecules, or vaccines that normally would not be absorbed through the gastrointestinal mucosal barrier. However, if the tightly regulated trafficking of macromolecules is jeopardized secondary to prolonged zonulin up-regulation, the excessive flow of nonself antigens in the intestinal submucosa can cause both intestinal and extraintestinal autoimmune disorders in genetically susceptible individuals. This new paradigm subverts traditional theories underlying the development of autoimmunity, which are based on molecular mimicry and/or the bystander effect, and suggests that the autoimmune process can be arrested if the interplay between genes and environmental triggers is prevented by re-establishing intestinal barrier competency. Understanding the role of zonulin-dependent intestinal barrier dysfunction in the pathogenesis of autoimmune diseases is an area of translational research that encompasses many fields.
Fasano
Alessio
A
University of Maryland School of Medicine, Mucosal Biology Research Center, Health Science Facility II, Baltimore, MD 21201, USA. afasano@mbrc.umaryland.edu
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000473:pathology; D002772:Cholera Toxin / Q000494:pharmacology / Q000627:therapeutic use*; D006242:Haptoglobins; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D007413:Intestinal Mucosa / Q000187:drug effects; D007422:Intestines / Q000473:pathology* / Q000502:physiology*; D010539:Permeability / Q000187:drug effects; D011498:Protein Precursors; D019108:Tight Junctions / Q000378:metabolism
D006242:Haptoglobins; D011498:Protein Precursors; C408043:zonulin; D002772:Cholera Toxin